Argent Capital Management LLC Sells 2,787 Shares of Medpace Holdings, Inc. $MEDP

Argent Capital Management LLC lowered its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 3.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 76,340 shares of the company’s stock after selling 2,787 shares during the period. Medpace accounts for about 1.2% of Argent Capital Management LLC’s holdings, making the stock its 27th biggest position. Argent Capital Management LLC owned approximately 0.27% of Medpace worth $42,876,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Quent Capital LLC acquired a new stake in Medpace in the 3rd quarter valued at $25,000. Optiver Holding B.V. acquired a new position in Medpace during the third quarter worth $27,000. Geneos Wealth Management Inc. raised its holdings in Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after buying an additional 37 shares during the last quarter. Quarry LP bought a new position in shares of Medpace in the third quarter valued at $35,000. Finally, Employees Retirement System of Texas acquired a new position in shares of Medpace during the second quarter valued at about $36,000. Institutional investors and hedge funds own 77.98% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on MEDP shares. Wall Street Zen upgraded shares of Medpace from a “hold” rating to a “buy” rating in a report on Saturday, January 17th. BMO Capital Markets reiterated a “market perform” rating on shares of Medpace in a research note on Wednesday, February 11th. Barclays raised Medpace from an “underweight” rating to an “equal weight” rating and set a $500.00 price objective for the company in a research note on Friday, March 6th. TD Cowen raised Medpace from a “sell” rating to a “hold” rating and cut their target price for the company from $462.00 to $419.00 in a research report on Wednesday, February 18th. Finally, Leerink Partners decreased their price target on Medpace from $575.00 to $485.00 and set a “market perform” rating for the company in a report on Wednesday, February 11th. Five analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $486.67.

Medpace Stock Performance

Shares of MEDP stock opened at $460.92 on Friday. The company has a market capitalization of $13.08 billion, a price-to-earnings ratio of 30.13, a PEG ratio of 2.18 and a beta of 1.44. Medpace Holdings, Inc. has a 52-week low of $250.05 and a 52-week high of $628.92. The company has a 50-day simple moving average of $511.94 and a two-hundred day simple moving average of $538.00.

Medpace (NASDAQ:MEDP) last announced its earnings results on Monday, February 9th. The company reported $4.67 earnings per share for the quarter, topping analysts’ consensus estimates of $4.18 by $0.49. The firm had revenue of $708.45 million for the quarter, compared to the consensus estimate of $689.53 million. Medpace had a return on equity of 118.82% and a net margin of 17.83%.The company’s revenue was up 32.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, sell-side analysts forecast that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Insider Activity

In other news, President Jesse J. Geiger sold 31,707 shares of Medpace stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $455.30, for a total transaction of $14,436,197.10. Following the sale, the president directly owned 15,000 shares in the company, valued at $6,829,500. The trade was a 67.88% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 20.30% of the stock is currently owned by corporate insiders.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.